Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica K Anderson

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Biorxiv : the Preprint Server for Biology|February 23, 2026
Reproducible Tools and Enhanced Computational Workflows for Batch Effect Evaluation of High-Throughput Data Using BatchQCJessica K Anderson, Jiwei Zhang, Xinshou Ge, et al.
Medrxiv : the Preprint Server for Health Sciences|January 16, 2026
Nasal Gene Expression in ART-Naive Adults with HIV and Pulmonary Tuberculosis in UgandaNisreen Khambati, Kattya Lopez Tamara, Elizabeth Nakabugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesRobert Z Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Biorxiv : the Preprint Server for Biology|February 23, 2026
Reproducible Tools and Enhanced Computational Workflows for Batch Effect Evaluation of High-Throughput Data Using BatchQCJessica K Anderson, Jiwei Zhang, Xinshou Ge, et al.
Medrxiv : the Preprint Server for Health Sciences|January 16, 2026
Nasal Gene Expression in ART-Naive Adults with HIV and Pulmonary Tuberculosis in UgandaNisreen Khambati, Kattya Lopez Tamara, Elizabeth Nakabugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesRobert Z Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, et al.
Pageof 1